Researching a new direction for OCD treatments

Dr. David Walling, Principal Investigator and CEO of Collaborative Neuroscience Network, is interviewed on national radio about a new OCD trial CNS is conducting in partnership with Biohaven Pharmaceuticals. Listen to the full interview below. To learn more about this study and others contact CNS today.

By | 2019-07-23T08:55:46+00:00 July 23rd, 2019|News, OCD|0 Comments